The use of cannabinoid therapy in treatment-refractory isolated REM sleep behavior disorder: a case report.

IF 2.9 3区医学 Q1 CLINICAL NEUROLOGY

Journal of Clinical Sleep Medicine Pub Date : 2025-07-01 DOI:10.5664/jcsm.11704

Sahej Samra, Hrayr Attarian, Roneil Malkani

引用次数: 0

Abstract

Current treatments for rapid eye movement sleep behavior disorder are not always effective and can lead to dose-limited adverse events, and new treatments are needed for this condition. We present a case of a patient with treatment-refractory isolated rapid eye movement sleep behavior disorder who had a dramatic and sustained improvement in dream enactment behaviors using oral tinctures containing cannabidiol and tetrahydrocannabinol without adverse events over 5 years of follow-up.

Citation: Samra S, Attarian H, Malkani R. The use of cannabinoid therapy in treatment-refractory isolated REM sleep behavior disorder: a case report. J Clin Sleep Med. 2025;21(7):1311-1313.

查看原文本刊更多论文

大麻素治疗难治性孤立性快速眼动睡眠行为障碍一例报告。

目前治疗快速眼动（REM）睡眠行为障碍（RBD）的方法并不总是有效，而且可能会导致剂量有限的不良反应，因此这种疾病需要新的治疗方法。我们介绍了一例难治性孤立型快速眼动睡眠障碍（RBD）患者的病例，该患者使用含有大麻二酚和四氢大麻酚的口服酊剂后，梦境行为得到了显著而持续的改善，随访 5 年无不良反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Sleep Medicine CLINICAL NEUROLOGY-

CiteScore

6.20

自引率

7.00%

发文量

321

审稿时长

1 months

期刊介绍： Journal of Clinical Sleep Medicine focuses on clinical sleep medicine. Its emphasis is publication of papers with direct applicability and/or relevance to the clinical practice of sleep medicine. This includes clinical trials, clinical reviews, clinical commentary and debate, medical economic/practice perspectives, case series and novel/interesting case reports. In addition, the journal will publish proceedings from conferences, workshops and symposia sponsored by the American Academy of Sleep Medicine or other organizations related to improving the practice of sleep medicine.